CAPLIN POINT LAB Latest Share Price (CAPLIPOINT)
TODAY IN ONE LINE
CAPLIPOINT fell 1.2% on light volume, lagging Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹21,207.26 Cr., it trades at a P/E of 31.23. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
CAPLIN POINT LAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 19.4% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 200.7% and Profit up 48.8%
- ●High Capital EfficiencyROCE of 19.7% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 18.8%
- ●Healthy Operating MarginsOPM is structurally strong at 67.2%
- ●High Promoter HoldingPromoters hold 70.6% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 19.6% outpacing sales growth of 14.4%
Latest CAPLIN POINT LAB News
What changed recently?
Recent events, corporate actions, and announcements.
CAPLIN POINT LAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for CAPLIN POINT LAB, framed against the sector median so the premium or discount is obvious at a glance.
CAPLIN POINT LAB trades at a P/E of 31.23× and P/B of 5.79×, against the Healthcare sector median P/E of 45.87×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
CAPLIN POINT LAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for CAPLIN POINT LAB — derived from the latest tape, not yesterday's close.
CAPLIN POINT LAB last traded at ₹2,810.8 with an intraday range of ₹2,759.6–₹2,845 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2810.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3021.47 | +210.67 | +7.49% |
| R3 | 2936.07 | +125.27 | +4.46% |
| R2 | 2890.53 | +79.73 | +2.84% |
| R1 | 2850.67 | +39.87 | +1.42% |
| PIVOT | 2805.13 | -5.67 | -0.20% |
| CURRENT | 2810.80 | — | — |
| S1 | 2765.27 | -45.53 | -1.62% |
| S2 | 2719.73 | -91.07 | -3.24% |
| S3 | 2679.87 | -130.93 | -4.66% |
| S4 | 2594.47 | -216.33 | -7.70% |
CAPLIPOINT is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹2782.2–₹2845
Trading Inside opening range
CAPLIN POINT LAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for CAPLIN POINT LAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
CAPLIN POINT LAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹21,207.26 Cr. and reported EPS of ₹23.27.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,937 | 2,187 ▲ 12.9% |
| Sales Growth YoY %Derived | 14.37% | 12.89% |
| Other Income | 96 | 116 ▲ 19.8% |
| Total Income | 2,034 | 2,303 ▲ 13.2% |
| 771 | 866 ▲ 12.3% | |
| Gross ProfitDerived | 1,167 | 1,322 ▲ 13.3% |
| Gross Margin %Derived | 60.21% | 60.42% |
| 520 | 561 ▲ 7.9% | |
| EBITDA (Operating Profit)Derived | 647 | 761 ▲ 17.6% |
| OPM %Derived | 33.39% | 34.79% |
| 67 | 74 ▲ 10.7% | |
| Profit Before Tax (PBT) | 677 | 803 ▲ 18.6% |
| 136 | 153 ▲ 12.8% | |
| Effective Tax %Derived | 20.05% | 19.07% |
| Total Profit for Period | 541 | 650 ▲ 20.1% |
| Less: Non-controlling Interests | 5 | 8 ▲ 77.6% |
| Net Profit (Owner's PAT)Derived | 536 | 641 ▲ 19.6% |
| Net Profit Margin %Derived | 27.68% | 29.32% |
| PAT Growth YoY %Derived | 17.33% | 19.57% |
| Earnings Per Share (EPS ₹) | 70.56 | 84.36 ▲ 19.6% |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% |
| Share of Profit from Associates/JVs | -0 | — ▲ 100.0% |
| Other Comprehensive Income (Net of Tax) | 27 | 142 ▲ 423.2% |
| Total Expenses (incl. D&A & Interest) | 1,357 | 1,500 ▲ 10.5% |
| Material Cost % of RevenueDerived | 12.82% | 16.33% |
| Employee Cost % of RevenueDerived | 9.17% | 9.11% |
| Other Cost % of RevenueDerived | 17.65% | 16.53% |
| Interest Coverage (x)Derived | 952.41x | 790.90x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 540 | 649 ▲ 20.2% | 863 ▲ 33.1% | 1,061 ▲ 22.9% | 1,269 ▲ 19.6% | 1,467 ▲ 15.5% | 1,694 ▲ 15.5% | 1,937 ▲ 14.4% | 2,187 ▲ 12.9% | |
| Sales Growth YoY %Derived | — | 20.16% | 33.07% | 22.95% | 19.61% | 15.54% | 15.50% | 14.37% | 12.89% | |
| Other Income | 13 | 19 ▲ 50.2% | 41 ▲ 117.2% | 24 ▼ 43.0% | 39 ▲ 64.6% | 56 ▲ 44.5% | 67 ▲ 19.6% | 96 ▲ 44.1% | 116 ▲ 19.8% | |
| Total Income | 553 | 668 ▲ 20.9% | 905 ▲ 35.5% | 1,085 ▲ 19.9% | 1,308 ▲ 20.6% | 1,523 ▲ 16.4% | 1,761 ▲ 15.7% | 2,034 ▲ 15.5% | 2,303 ▲ 13.2% | |
238 | 289 ▲ 21.2% | 413 ▲ 43.1% | 472 ▲ 14.2% | 558 ▲ 18.2% | 663 ▲ 19.0% | 724 ▲ 9.2% | 771 ▲ 6.4% | 866 ▲ 12.3% | ||
| Gross ProfitDerived | 302 | 360 ▲ 19.3% | 450 ▲ 25.0% | 590 ▲ 31.0% | 712 ▲ 20.8% | 804 ▲ 12.9% | 970 ▲ 20.7% | 1,167 ▲ 20.3% | 1,322 ▲ 13.3% | |
| Gross Margin %Derived | 55.88% | 55.48% | 52.14% | 55.55% | 56.08% | 54.78% | 57.25% | 60.21% | 60.42% | |
107 | 129 ▲ 20.3% | 190 ▲ 47.7% | 261 ▲ 37.3% | 317 ▲ 21.6% | 362 ▲ 14.3% | 418 ▲ 15.5% | 520 ▲ 24.2% | 561 ▲ 7.9% | ||
| EBITDA (Operating Profit)Derived | 195 | 231 ▲ 18.8% | 260 ▲ 12.4% | 329 ▲ 26.4% | 395 ▲ 20.1% | 441 ▲ 11.8% | 551 ▲ 25.0% | 647 ▲ 17.3% | 761 ▲ 17.6% | |
| OPM %Derived | 36.08% | 35.66% | 30.13% | 30.97% | 31.09% | 30.07% | 32.55% | 33.39% | 34.79% | |
19 | 23 ▲ 23.2% | 32 ▲ 36.0% | 39 ▲ 20.7% | 48 ▲ 23.4% | 46 ▼ 3.7% | 54 ▲ 18.8% | 67 ▲ 22.2% | 74 ▲ 10.7% | ||
| Profit Before Tax (PBT) | 188 | 227 ▲ 20.4% | 269 ▲ 18.8% | 314 ▲ 16.4% | 386 ▲ 23.0% | 451 ▲ 17.0% | 564 ▲ 25.1% | 677 ▲ 19.9% | 803 ▲ 18.6% | |
44 | 50 ▲ 15.0% | 54 ▲ 8.1% | 62 ▲ 14.3% | 77 ▲ 24.4% | 74 ▼ 3.9% | 103 ▲ 38.5% | 136 ▲ 31.7% | 153 ▲ 12.8% | ||
| Effective Tax %Derived | 23.22% | 22.18% | 20.18% | 19.83% | 20.05% | 16.48% | 18.25% | 20.05% | 19.07% | |
| Total Profit for Period | 145 | 177 ▲ 22.1% | 215 ▲ 21.8% | 251 ▲ 16.9% | 308 ▲ 22.7% | 377 ▲ 22.2% | 461 ▲ 22.4% | 541 ▲ 17.3% | 650 ▲ 20.1% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 92.4% | 0 ▲ 752.6% | 9 ▲ 12000.4% | — ▼ 100.0% | 1 | 4 ▲ 493.2% | 5 ▲ 10.4% | 8 ▲ 77.6% | |
| Net Profit (Owner's PAT)Derived | 145 | 177 ▲ 21.9% | 215 ▲ 21.8% | 242 ▲ 12.7% | 308 ▲ 27.3% | 376 ▲ 22.0% | 457 ▲ 21.5% | 536 ▲ 17.3% | 641 ▲ 19.6% | |
| Net Profit Margin %Derived | 26.82% | 27.22% | 24.91% | 22.83% | 24.30% | 25.65% | 26.98% | 27.68% | 29.32% | |
| PAT Growth YoY %Derived | — | 21.95% | 21.77% | 12.68% | 27.31% | 21.98% | 21.48% | 17.33% | 19.57% | |
| Earnings Per Share (EPS ₹) | 19.15 | 23.35 ▲ 21.9% | 28.42 ▲ 21.7% | 32.03 ▲ 12.7% | 40.70 ▲ 27.1% | 49.57 ▲ 21.8% | 60.19 ▲ 21.4% | 70.56 ▲ 17.2% | 84.36 ▲ 19.6% | |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.2% | 8 ▲ 0.2% | 8 ▲ 0.1% | 8 ▲ 0.1% | 8 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | — | -0 | — ▲ 100.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | -0 ▼ 133.4% | 17 ▲ 6619.4% | -7 ▼ 143.0% | 14 ▲ 299.2% | 43 ▲ 199.8% | 11 ▼ 73.2% | 27 ▲ 136.4% | 142 ▲ 423.2% | |
| Total Expenses (incl. D&A & Interest) | 364 | 441 ▲ 21.1% | 635 ▲ 44.1% | 771 ▲ 21.4% | 922 ▲ 19.6% | 1,071 ▲ 16.2% | 1,197 ▲ 11.7% | 1,357 ▲ 13.4% | 1,500 ▲ 10.5% | |
| Material Cost % of RevenueDerived | 16.71% | 14.66% | 12.53% | 12.23% | 15.15% | 15.21% | 14.16% | 12.82% | 16.33% | |
| Employee Cost % of RevenueDerived | 7.25% | 7.26% | 7.85% | 9.66% | 9.08% | 9.34% | 8.48% | 9.17% | 9.11% | |
| Other Cost % of RevenueDerived | 12.55% | 12.56% | 14.16% | 14.92% | 15.91% | 15.37% | 16.23% | 17.65% | 16.53% | |
| Interest Coverage (x)Derived | 2,872.13x | 3,465.12x | 714.57x | 183.44x | 496.81x | 507.78x | 638.46x | 952.41x | 790.90x |
CAPLIN POINT LAB segment analysis : revenue and profit mix.
Disclosed business segments at CAPLIN POINT LAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
CAPLIN POINT LAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for CAPLIN POINT LAB.
Our AI distills the core fundamental drivers supporting CAPLIN POINT LAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
CAPLIN POINT LAB's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 31.46% and net margin 29.32% significantly exceed pharmaceutical sector peers.
ROE 17.89% and ROCE 18.40% demonstrate highly efficient capital deployment and returns.
Debt-to-equity ratio 0.00x reflects fortress balance sheet with substantial financial flexibility.
Promoter holding 70.57% ensures strong management alignment and long-term strategic commitment.
Latest quarterly EPS grew 19.3% YoY; TTM EPS grew 19.4% YoY despite market headwinds.
Key Risks.
P/E ratio 30.42x significantly exceeds sector median, limiting upside potential for new investors.
Dividend yield 0.29% remains unattractive for income-focused investors seeking regular returns.
52-week price range ₹1,500.30 to ₹2,877.30 signals elevated volatility and execution risk.
Payout ratio 11.46% indicates minimal cash returned to shareholders despite strong profitability.
Free cash flow negative ₹9.99 crore in FY2026 raises concerns about capital allocation efficiency.
Flip Conditions.
Valuation risk. a P/E above 41 (~0.9× the sector multiple of 45.9) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 14% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.13%.
CAPLIN POINT LAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — CAPLIN POINT LAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
CAPLIN POINT LAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for CAPLIN POINT LAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
CAPLIN POINT LAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for CAPLIN POINT LAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in CAPLIN POINT LAB stood at 34.9% of traded volume, against a 20-day average of 41.7%.
CAPLIN POINT LAB announcements: results, concalls, ratings, M&A.
Filings CAPLIN POINT LAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
CAPLIN POINT LAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 99 documents below.
Copy of Newspaper Publication
Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'.
Updates
Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.
Shareholders meeting
Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026
Spurt in Volume
Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest…
Investor decks & rating reports.
CAPLIN POINT LAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue CAPLIN POINT LAB has declared, sequenced by announce and record date.
CAPLIN POINT LAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About CAPLIN POINT LAB: business, sector, key facts.
What CAPLIN POINT LAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
CAPLIN POINT LAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: CAPLIPOINT, BSE: 524742.
Caplin Point Laboratories Limited (CPL) is a prominent Indian pharmaceutical company specializing in the development, manufacturing, marketing, and export of generic and branded pharmaceutical formulations. Established in 1990 and headquartered in Chennai, India, CPL has built a significant presence in the Indian pharmaceutical market and beyond through its diverse product portfolio and extensive distribution network.
The company's product range is exceptionally broad, encompassing a wide array of dosage forms to cater to various therapeutic needs. This includes solid oral formulations like tablets and capsules, various injectable options such as injections, powder for injections, and pre-filled syringes, and a variety of topical preparations such as ointments, creams, gels, and sprays. CPL also manufactures liquid orals, softgel capsules, ophthalmic products, suppositories, ovules, pre-mix bag formulations, inhalers, dry syrups, lyophilized vials, emulsion injections, and IV infusions. This extensive portfolio allows CPL to address a large spectrum of medical conditions and patient demographics.
CPL's business model focuses on both generic and branded pharmaceutical products. While the production and distribution of generic medications form a substantial part of their operations, enabling them to offer cost-effective alternatives to branded drugs, they also actively develop and market their own branded products, allowing them to participate in both value and volume-based segments of the market. This dual approach provides a degree of stability and diversification, mitigating risks associated with relying solely on one market segment.
The company’s success is driven by its integrated approach, encompassing all stages of the pharmaceutical value chain, from research and development to manufacturing and distribution. This vertical integration provides greater control over quality, cost, and time-to-market, contributing to CPL's competitiveness in a highly competitive global pharmaceutical landscape. Their commitment to exports further enhances their market reach and revenue streams. In short, CPL is a fully integrated pharmaceutical company focused on delivering a diverse range of quality medications to both domestic and international markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about CAPLIN POINT LAB (CAPLIPOINT).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of CAPLIN POINT LAB (CAPLIPOINT)?
The current share price of CAPLIN POINT LAB (CAPLIPOINT) is ₹2,810.80. Today, the stock has declined by ₹34.20 (1.2%), trading in a range of ₹2,759.60 to ₹2,845.00. The stock opened at ₹2,845.00 with a trading volume of 2,08,526 shares.
02Is CAPLIN POINT LAB stock a good investment for long-term?
CAPLIN POINT LAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹21,207.26 Cr., P/E ratio of 31.23, ROE of 18.79%, and ROCE of 19.67%. The dividend yield stands at 0.25%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of CAPLIN POINT LAB stock?
The 52-week high price of CAPLIN POINT LAB (CAPLIPOINT) is ₹2,877.30, while the 52-week low is ₹1,500.30. Currently trading at ₹2,810.80, the stock is 87.35% above its 52-week low and 2.31% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy CAPLIN POINT LAB stock at the current price?
Whether to buy CAPLIN POINT LAB stock at ₹2,810.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 31.23 and P/B ratio of 5.79. Today's performance shows a loss of 1.2%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of CAPLIN POINT LAB and when is the next dividend?
CAPLIN POINT LAB offers a dividend yield of 0.25%, which means for every ₹100 invested at the current price of ₹2,810.80, you can expect to receive approximately ₹0.25 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of CAPLIN POINT LAB?
CAPLIN POINT LAB's key financial metrics include: P/E Ratio: 31.23, P/B Ratio: 5.79, ROE: 18.79%, ROCE: 19.67%, Dividend Yield: 0.25%, EPS: ₹23.27, Book Value: ₹477.66, and Debt-to-Equity: 0. The company's market cap stands at ₹21,207.26 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is CAPLIN POINT LAB stock performing today in the market?
CAPLIN POINT LAB stock opened at ₹2,845.00 and is currently trading at ₹2,810.80, showing a decline of ₹34.20 (1.2%). The intraday high is ₹2,845.00 and low is ₹2,759.60. The trading volume stands at 2,08,526 shares, indicating moderate market participation today.
08What is the P/E ratio of CAPLIN POINT LAB and what does it indicate?
CAPLIN POINT LAB has a Price-to-Earnings (P/E) ratio of 31.23, which means investors are willing to pay 31.23 for every ₹1 of earnings. With an EPS of ₹23.27, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about CAPLIN POINT LAB (CAPLIPOINT) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.